Enhanced care package to improve survival in advanced HIV disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase III, cluster randomized trial aims to evaluate the survival benefit of an enhanced package of care for patients with advanced HIV disease in Uganda. The study will involve HIV-infected adults with CD4 counts below 200 cells/µL and will compare an enhanced care package, including point-of-care CD4 testing and opportunistic infection prophylaxis, against standard care. Over a duration of 5 years, the trial will assess 24-week survival rates and retention in care among participants. The enhanced package includes innovative screening and treatment options for opportunistic infections.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 years
* CD4\<200 cells/µL
* Ability and willingness to give informed consent for the enhanced package of care arm.

Exclusion Criteria:

* Known virologic suppression (viral load \<1000 copies/mL) within prior 3 months
* Cannot or unlikely to attend regular clinic visits

Where it's running

• kisugu health center IV
  Kampala, Uganda Recruiting

Study contacts

• Study coordinator: Radha Rajasingham, MD
• Email: radha@umn.edu
• Phone: 612 626-8171

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation

  This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.

  Recruiting at 2 sites Makerere University · Kampala and 1 other locations · NCT07844876

• SCD SIMCS: a mobile system to help screen newborns for sickle cell disease in Ugandan clinics

  A cluster randomized trial will test a mobile information system (SIMCS) that helps health workers screen newborns for sickle cell disease and coordinate care, compared with usual screening in Uganda.

  Recruiting Makerere University · Jinja · NCT07610239

• Call for Life Sepsis

  This trial tests an Interactive Voice Response system at the time of hospital discharge to see if it can reduce sepsis-related deaths after discharge for adults with sepsis in Uganda hospitals.

  Recruiting Makerere University · Kampala and 1 other locations · NCT07407868

• Medical drones to deliver HIV medicines and lab samples in the Kalangala islands

  This trial tests whether delivering antiretroviral medicines by medical drones can help people with HIV in Kalangala islands achieve undetectable viral loads.

  Recruiting at 2 sites Makerere University · Kalangala, Ssese and 1 other locations · NCT06678022

• Using Doxycycline to Prevent Lung Fibrosis in Tuberculosis Patients

  This study is testing if doxycycline can help prevent lung damage in people with advanced tuberculosis while they receive standard treatment.

  Recruiting Phase 2 Makerere University · Kampala, Kampala and 1 other locations · NCT06477185

• Single dose treatment for asymptomatic cryptococcal antigenemia

  This study is testing if a single dose of a special antifungal treatment combined with standard care can help people in Uganda with a certain type of fungal infection avoid getting sicker and live longer.

  Recruiting Phase 2/3 Makerere University · Kampala · NCT03945448

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.